Back to Peptides
Argipressin
Cardiovascular & AntiplateletArgipressin (vasopressin) is a synthetic analog of antidiuretic hormone used in acute care to manage hypotension in vasodilatory shock and control excessive diuresis in diabetes insipidus. It acts on V1 and V2 receptors to regulate vascular tone and water reabsorption in the kidneys.
Reconstitute
1 mL BAC + 20mg vial
200 mcg/unit
Daily Range
0.01–0.04 units/min Intravenous (IV)
Continuous infusion
Standard Dose
0.03 units/min
Cycle
4–8 weeks
then reassess
Argipressinvasopressinvasodilatory shockdiabetes insipidusV1 V2 receptor agonist
Dosing & Reconstitution Guide
In hospital settings, argipressin is administered in microgram doses via IV. It is not approved for use outside of supervised care.
Standard / Gradual Approach
20mg VialstandardPhaseDoseVolume
Initial0.01 units/minIV infusion titrated
Titrate up0.02 units/minIV infusion titrated
Maximum0.04 units/minIV infusion titrated
Protocol Summary
Intravenous (IV): Continuous infusion · Dose range 0.01–0.04 units/min with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
IV
Continuous infusion with titration between 0.01 to 0.04 units/min based on hemodynamic response. Monitoring is critical in ICU settings.
🧪 Quick Start
BAC Water
500 mL
Starting Dose
0.01 units
Potential Benefits & Use Cases
Argipressin is an emergency-use medication and is not authorized for general therapeutic use.
Regulates renal water reabsorption via V2 receptor activation
Causes vasoconstriction through V1 receptors
Used in emergency medicine and ICU studies for hypotension
Studied in models of diabetes insipidus and adrenal insufficiency
Explored for reducing bleeding in surgical models
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to V1 receptors on vascular smooth muscle to induce vasoconstriction
→Activates V2 receptors in renal collecting ducts, increasing aquaporin insertion and water reabsorption
→Restores arterial pressure by elevating systemic vascular resistance in shock
→Reduces free water clearance in the kidney without increasing sodium retention
Lifestyle & Optimization
timing
Hospital/ICU setting only. IV infusion with continuous hemodynamic monitoring.
diet
Ensure adequate volume resuscitation before and during therapy.
exercise
Not applicable — acute care vasopressor.
sleep
Not applicable — acute care setting. Monitor for digital ischemia, hyponatremia, and cardiac arrhythmias.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Hyponatremia
• Abdominal cramps
• Headache
• Flushing
Contraindications & Warnings
• Can cause water intoxication and electrolyte imbalance if not monitored closely
• Use cautiously in patients with coronary artery disease or chronic kidney disease
Long-Term Safety Data
• May cause long-term changes in renal sodium handling if misused
• Tachyphylaxis may develop in prolonged shock states
🧮 Dose Calculator
Concentration
200.0
mcg/unit
Draw Volume
3
units (0.030 mL)
For a 500 mcg dose, draw 3 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Not used via this route due to short half-life and low efficacy
Oral Administration
Poor bioavailability due to enzymatic breakdown
Half-Life
10 to 35 minutes
Degradation
Rapid hepatic and renal enzymatic degradation
Tissue Specificity
Targets vascular smooth muscle and renal collecting ducts
⚗️
Peptide Details
Molecular Weight
1084.24
Formula
C46H65N15O12S2
Sequence
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
⚖️
Legal Status & Regulatory
RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved
Storage Instructions
Lyophilized (Powder)
Store at 20–25°C (room temperature). Protect from light.
Reconstituted (Mixed)
Diluted IV solutions stable for 18 hours at room temperature or 24 hours refrigerated.